Sponsorship and Funding for Gene Therapy Trials in the United States
Authors:
- 3 March 2020
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA
- Vol. 323 (9) , 890-891
Abstract
This study characterizes government, academia, and private funding for gene therapy trials in the United States by technology type and therapeutic and disease aKeywords
This publication has 7 references indexed in Scilit:
- Single-Dose Gene-Replacement Therapy for Spinal Muscular AtrophyNew England Journal of Medicine, 2017
- Faculty Opinions recommendation of Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.2016
- Trends in National Institutes of Health Funding for Clinical Trials Registered in ClinicalTrials.govJAMA, 2015
- Improving Single Injection CSF Delivery of AAV9-mediated Gene Therapy for SMA: A Dose–response Study in Mice and Nonhuman PrimatesMolecular Therapy, 2015
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen ReceptorJournal of Clinical Oncology, 2015
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid LeukemiaNew England Journal of Medicine, 2011
- Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trialThe Lancet, 2009